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ABSTRACT
Alzheimer’s disease (AD) leads to neurodegeneration resulting in cognitive and physical
impairments. AD is denoted by accumulation of intracellular neurofibrillary tangles, known as
tau, and extracellular plaques of the amyloid beta protein (Aβ). Aβ results from the proteolytic
cleavage of the amyloid precursor protein (APP) by [Symbol]- and [Symbol]-secretases in the
amyloidogenic pathway. Although, Aβ has been widely studied for neurodegeneration, the role
of APP in both, the healthy and diseased conditions, has not yet been entirely understood. The
function that APP has in neural stem cell (NSC) proliferation, differentiation, and migration
during adult neurogenesis has been previously studied. Additionally, APP has be shown to be
overexpressed after neural damage resulted from conditions, such as AD and traumatic brain
injury (TBI). In this study, the role of APP in in vitro damaged neural tissue cells was further
investigated by evaluating neural progenitor cell proliferation, migration, and differentiation after
a scratch assay. For these purposes, induced pluripotent stem (iPS) cells from AD patients were
differentiated into neural progenitor cells to model the disease conditions and later treated with
Phenserine to reduce their levels of APP expression. The results suggested that APP may
enhance neural progenitor cell proliferation and glial differentiation while inhibiting neural
progenitor cell migration and neuronal cell specialization after neural tissue damage.
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INTRODUCTION
Approximately 5.7 million Americans aged ≥ 65 were diagnosed with Alzheimer’s
Disease (AD) on 2018, making it the 5th most common cause of death in the United States [1].
AD is a neurodegenerative disease that causes progressive cognitive impairment in earlier stages
and gradual physiological dysfunction in later stages. There are not yet specific treatments to
prevent or cure AD. However, current research efforts focus on further understanding the
pathological characteristics of AD, and how these can be targeted for future treatments. Besides
neurodegeneration, AD is also characterized by accumulation of intracellular neurofibrillary
tangles and extracellular senile plaques [1,2]. The neurofibrillary tangles, known as tau tangles,
have been shown to prevent the transport of crucial molecules inside neurons. While, the senile
plaques are accumulations of the β-amyloid (Aβ) fragments, which are thought to interfere with
neural synapsis and contribute to neuronal cell death [1]. Understanding the molecular
mechanisms around the formation and accumulation of Aβ fragments and its effects on the
pathology of AD has been of great importance for the research community over the years.
Aβ accumulations are found in the brains of AD patients as oligomers, which are formed
after proteolytic cleavage of the amyloid precursor protein (APP) by -secretase, - secretase,
and a complex of γ-secretase enzymes [3,4]. Among the peptides derived from APP, Aβ40 and
Aβ42 are associated with AD pathology, of which Aβ42 has been found to be insoluble and
deleterious, while Aβ40 is soluble and most commonly found in AD and healthy brains (Figure 1)
[5]. Since it is though that Aβ accumulation is a major cause for the loss of synapses that leads to
the loss of memory in AD patients, studies inhibiting both Aβ and APP have been widely
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performed. However, drug treatments targeting APP and γ- secretase to reduce or eliminate Aβ
production have shown to have deleterious effects including, alteration of cognition and emotion,
and deterioration in hippocampal synaptic plasticity and memory [6]. Such findings highlight the
importance of the molecular mechanisms underlying APP and Aβ for the maintenance of the
healthy brain and point out the need for further studies of the roles that these proteins play.
Much attention has been given to studies focusing on the molecular mechanisms of Aβ
and its function on both, healthy and AD brains. Thus, it would be beneficial to first evaluate the
role of its precursor protein to understand the reasons behind Aβ accumulation in the AD brain.
Studies in vitro and in vivo of AD have inhibited APP to investigate the effects that this protein
has on the healthy and diseased brains. Previous research has indicated that, among many roles,
APP is involved in maintenance of dendritic spine structures [7], modulation of microglia
phenotype, inflammatory response, cell-cell adhesion [8], neural stem cell differentiation and
migration, and adult neurogenesis [9]. These findings led to the conclusion that APP proteolytic
products, especially Aβ, are found in large quantities in the diseased brains due to the function of
APP in maintaining and developing the central nervous system (CNS).
The role of APP on adult neurogenesis and its contribution to regeneration after cell
damage are of great interest for this study. Neurogenesis has been postulated as a novel
therapeutic approach to treating neurodegenerative diseases [10]. Previous research has revealed
the importance of APP in the proliferation of neural progenitor cells; and how dysfunction of
APP could not only contribute to the aggregation of toxic Aβ peptides, but also lead to the
impaired hippocampal neurogenesis related to AD [9,11, 12]. Considering that APP has a
specific role in neurogenesis, evaluating its significance in the repair process of damaged neural
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tissue can also justify why APP and its proteolytic products are found in great abundance in the
AD brain. Aβ deposition and APP upregulation have been linked to pathological conditions, such
as traumatic brain injury (TBI), where tissue damage in specific regions of the brain also results
in inflammation, which is also common in AD [13]. IL-1β, an inflammatory cytokine found in
TBI, was shown to be produced in glial cells surrounded by amyloid plaques in AD [14],
indicating that regulation of APP expression when TBI is present was associated with IL-1β [13].
This implies that APP may be upregulated or overexpressed when neural tissue damage, leading
to neuronal loss, is present.
The function that APP may have in neurogenesis and inflammatory responses suggests
that APP production upon neural tissue damage may have a key role in the proliferation and
migration of neural progenitors for tissue damage repair. Thus, this study aims to understand
how APP influences wound healing after neural damage and disruption of neural cell
connections. Neural progenitors (NP) derived from induced pluripotent stem cells (iPS) will be
used as a in vitro model for both, the AD and the healthy brain (Control), for later comparison of
the expression of APP in both conditions. iPS cells represent a novel model for
neurodegenerative diseases, such as AD, because they maintain genotypic characteristics of the
disease [3]. Thus, iPS cells allow for the study of AD by using any type of the patient’s somatic
cells, which will become pluripotent and later specialized into a targeted cell for pathological
studies. The NPs-iPS cells will be exposed to a scratch assay that will mimic tissue damage by
disrupting cell connections. Migration and proliferation processes will be evaluated as well as
neural progenitor cell specialization to further understand how APP influences all these
mechanisms in the AD.
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BACKGROUND
The development of the nervous system and its regeneration are relevant for therapies
involving neurodegenerative diseases [10]. In the past, it was thought that the nervous tissue
could not be regenerated after birth, however the development of sophisticated techniques made
it possible to locate areas in the brain were neural regeneration happens [9, 15]. Neurogenesis, in
the adult mammalian brain compromises three areas, the subventricular zone, the olfactory bulb,
and the hippocampus [10]. Adult neurogenesis requires NSCs proliferation, differentiation, and
migration [9] to areas of the brain that require high plasticity [10]. The functional significance of
adult neurogenesis remains unknown, nonetheless its importance has been linked to learning and
memory processes [12].
In AD, hippocampal adult neurogenesis has been shown to be altered, but whether or not
such alteration is positive or negative is still controversial. On one hand, impaired hippocampal
adult neurogenesis has been linked to impairment of learning, memory, and cognitive functions
in AD [12, 16]. Early impairment of adult neurogenesis is thought to enhance the progression of
the disease [18]. Other studies have shown that hippocampal adult neurogenesis is increased in
AD as a mechanism to partially compensate for the loss of neurons [17]. This could be because
internal factors may promote the regenerative and recovery process of the brain. This
discrepancy rises because it has been shown that various molecular players involved in AD
pathology, like APP, are also involved in the process of hippocampal neurogenesis (Figure 2)
[18].
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APP is a single-pass transmembrane protein that is rapidly metabolized in neurons [6].
APP is best known by its proteolytic products that highlight two distinctive pathways, nonamyloidogenic and amyloidogenic, which give rise to the Aβ40 and Aβ42 peptides associated with
AD (Figure 1). Among multiple functions that have been proposed for APP, its role in
embryonic and adult neurogenesis [12] is of great importance for further understanding of AD
and development of treatments against this disease. Studies in vivo and in vitro have
demonstrated the importance of APP in regulating human NSCs (hNSCs) migration and
differentiation [9, 19], which is important for the neurogenesis process in the normal adult brain.
Other studies have also postulated that APP has a function in neural progenitor cell migration
and axonal growth after neuronal damage or injury in Drosophila [19, 20] and cell culture [21].
These findings suggest that when damage of neuronal cells happen in neurodegenerative diseases
like AD, APP may serve a crucial role in the processes that aim for restauration of the normal
brain function.
APP has also been a major target for drugs that aim to reduce the production of A.
Previous research has demonstrated that Phenserine, an inhibitor of cholinesterase, can reduce
the levels of APP by posttranscriptional regulation and subsequently the secretion of its
proteolytic products in vivo and in vitro [22]. Phenserine regulates APP through an iron element
located in the 5’untranslated region of the APP mRNA [22]. Shaw et. al. (2001) suggested that
for a reduction of APP of nearly 50%, a specific concentration of Phenserine must be added to
cells, in that case human glioblastoma and astrocytoma, for a specific period of time [22]. Using
Phenserine to reduce APP production will serve to understand the role of APP by altering the
normal conditions in which the NP-IPS cells produce this protein. Cell functions and the
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influence of agents like Phenserine can also be evaluated to see what secondary effects the
reduction of APP may have.
Studies of neurodegenerative diseases have been limited by few human disease models,
the reliability of human tissue [3], and ethical issues. Newer discoveries have allowed for
somatic cells to be reprogramed into stem cells that will be later differentiated in any type of cell
that they are orchestrated to. The reprogramed cells are referred as iPS cells and represent a
novel technique to model and treat neurodegenerative diseases [3]. iPS cells are differentiated
into neural stem cells in vitro by using specific signal molecules to replicate the natural processes
that drive neurogenesis [23]. Of these approaches, the inhibition of SMAD pathways has shown
to be sufficient for conversion of iPS cells into NSCs in adherent conditions [24]. iPS cells can
be used to mimic neurodegenerative diseases in vitro because disease-specific genetic marks can
be conserved [3, 25]. Thus, in vitro models of AD using iPS cells will allow to further study the
mechanisms involved in the disease and can serve as a guide for techniques used in in vivo
studies or clinical trials.
Scratch assays allow for in vitro studies of regeneration as well as the agents involved.
Axonal out-growth has been previously studied upon injury to evaluate the factors related to
axonal regrowth and connectivity, and also indicated that scratch assays can be used to evaluate
gliosis and astrocyte changes as well as axonal regrowth [25]. The efficiency of the scratch assay
in studies involving neural cells suggests that it can be used as a model for evaluating the
response that such cells have upon changes of factors that are key to regeneration processes. In
this study, by addition of Phenserine, which may downregulate APP on NP – iPS cells.
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OBJECTIVES
1. To differentiate Alzheimer's patient specific NSC-iPS cells into neural progenitor cells
2. To model neural tissue damage of neural progenitor cells through a scratch assay and
analyze cell migration, proliferation, and cell specialization using fluorescent microscopy
techniques
3. To understand how APP influences neuroregeneration of neural progenitor cells after
injury by analyzing APP concentration using RT-PCR and fluorescent microscopy
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HYPOTHESIS
High expression of APP and its proteolytic products are seen as hallmarks for
Alzheimer’s disease indicating the possible role of APP in processes involving
neurodegeneration. APP has been shown to play multiple roles regarding development and the
maintenance of the normal functioning of the brain.
It is hypothesized that APP is highly expressed on Alzheimer’s disease due to its role on
cell migration, proliferation, and differentiation after neural tissue damage. The experiments to
be done in this thesis are attended to address what the role of APP is in the Alzheimer's disease
condition. Previous in vivo and in vitro studies have demonstrated the role of APP in both
neurogenesis and neuroregeneration, which support the idea that APP plays an important role in
regulation of processes involving healing.
A novel model using patient-specific neural progenitor cells derived from induced
pluripotent stem cells is proposed to evaluate the role that APP may have in the human adult
brain upon tissue damage. Based on the information reviewed for this study, a scratch assay has
not yet been performed that can indicate how APP may affect cell migration, proliferation, and
differentiation upon tissue damage in vitro. Thus, it has been proposed to evaluate the possible
role of APP these cell mechanisms upon an in vitro neural tissue damage model.
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METHODS
Neural Differentiation of iPS Cells through Dual SMAD Inhibition
The cells used for this study were neural stem cells (NSCs) derived from induced
pluripotent stem (iPS) cell lines generated by the dual SMAD inhibition methodology
proposed by Chambers [24]. iPS cell lineages CW0018 (Control) and CW0064 (familial AD)
from MyCellProducts were expanded and later treated with SMAD signaling inhibitors,
Noggin and SB431542, for neural conversion (Figure 4). The resultant cells were then frozen
using Synth-a-Freeze™ medium (Gibco®) and stored at in liquid nitrogen.
NSCs-iPSCs Expansion & Differentiation into Neural Progenitors
Frozen Control and AD NSCs derived from iPS cells were thawed at 37°C inside a
water bath for 1-2 minutes followed by quick passaging to T-75 suspension flasks containing
20mL of pre-incubated (37°C, 5% CO2) hNSC Media (500 mL DMEM/F-12, 1X B-27,
0.2ng/mL EGF, 2.0ng/mL rhFGF, 0.5U/mL Herparin, 1X antibiotic). NSCs-iPS were
maintained with 50% media change every 3-4 days and incubated at 37°C, 5% CO2 to allow
cells to grow into neurospheres. Every 1-2 weeks, neurospheres were mechanically
dissociated and split/passaged to enhance NSCs-iPS proliferation and formation of new
neurospheres. After three passages, NSCs-iPS were induced to differentiate using media
containing DMEM F12, 10% FBS, 1% antibiotic (NT2 media). Cells were maintained by
performing 50% media exchange every 5-7 days with NT2 media and incubated at 37°C, 5%
CO2 for two weeks. Following differentiation, all media was collected in 50 mL conical
tubes, and adhered cells were lifted using Versene 1X (Gibco® Life Technologies). 4mL of
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Versene 1X was added to the cells, incubated for 5 minutes at 37°C, 5% CO2, and later
neutralized using 4mL of NT2 media. The contents of the flasks were added to the 50mL
tubes, and cells were centrifuged at 1,200 rpm for 5 minutes. Supernatant was removed, and
pellet was dissociated in NT2 media for cell count. 20,000 cells per well were seeded on
seven 12-well adherent plates treated with polystyrene (FALCON ®). Cells were maintained
using NT2 media by 50% media change every 5 days and incubation at 37°C, 5% CO2 until
100% confluency was reached.
Neural Progenitor Cell Labeling
Vybrant™ Dio (Thermo Fisher Scientific) cell labeling solution was added to neural
progenitor (NP) cells obtained from differentiation of NSCs-iPS in order to track NP cells. A
concentration of 5ul/mL of Vybrant Dio was added to each well for a final volume of 400uL.
Cells were then incubated for one hour and 15 minutes at 37°C, 5% CO2. Vybrant Dio was
then removed followed by three washes with 1X Phosphate Buffered Saline (PBS) pH 7.4 to
remove any residuals from the cells. New NT2 media was added and cells were incubated for
24 hours before drug treatment.
Phenserine Treatment for Amyloid Precursor Protein Reduction
Neural progenitor (NP) cells obtained from differentiation of NSCs-iPS with NT2
media were treated with Phenserine Tartrate to reduce expression of APP. Based on Shaw’s
[22] findings for APP reduction, a concentration of 50uM was used to test reduction of APP
synthesis by about 50% in 16 hours. A 10,000uM stock solution was prepared using 0.1g of
Phenserine Tartrate and 35 mL of molecular grade water. A 50uM Phenserine Tartrate
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solution made from stock using NT2 media. Old NT2 media was removed, and the 50uM
solution in the positive control cells to a final volume of 1mL per well. Incubation took place
for a period of 16 hours at 37°C, 5% CO2.
Scratch Assay
Immediately after Phenserine treatment for 16 hours, a vertical 1.5 mm scratch was
performed using a 1 mL pipette tip. After this, the 50uM Phenserine Tartrate solution was
removed and replaced with new fresh NT2 media. Cells were incubated at 37°C, 5% CO2 for
5 days. In order to follow the neurogenesis process of the NPCs, pictures were taken at 2, 24,
48, and 120 hours using 20X magnification in a fluorescent microscope. Images were
captured at each time point on a specific area towards the left side of the scratch.
Immunocytochemistry of Neural Progenitors Treated with Phenserine and Scratch Assay
Following 120 hours after the scratch assay, NP-iPS cells were fixed using 100% iced
cold methanol for 15 minutes at -20°C and washed three times with 1X PBS.Cells were
permeabilized and membrane was blocked using a blocking buffer (1X PBS, 5% normal
donkey serum, 0.3% Triton™ X-100) for 60 minutes at room temperature followed by three
washes with 1X PBS. Plates containing Vybrant™ Dio were treated with anti BIII-tubulin
antibody (1:1000) (Thermo Fisher Scientific). For the other plates, half of them were treated
with anti BIII-tubulin (1:000) and anti GFAP (ASTRO6) (1:200) (Thermo Fisher Scientific)
antibodies, and the other half were treated with anti BIII-tubulin (1:1000) and anti APP22C11 (2.5:1,000) (abcam) antibodies. The cells were incubated overnight at 4°C. Following
incubation, cells with BIII-tubulin only were treated with donkey anti-rabbit IgG TRITC
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(1:200). The rest of the cells were treated with donkey anti-rabbit IgG TRICT and donkey
anti-mouse IgG FITC (1:200) (Jackson Immuno Research Laboratories, INC) and incubated
at 4°C overnight. After three washes with 1X PBS, DAPI (100:900) was added to all the cells
followed by a 1x PBS wash. Pictures were taken towards the left side of the scratch using
20X magnification in a fluorescent microscope.
RNA Isolation of Neural Progenitors Treated with Phenserine and Scratch Assay using
TRIzol

Total RNA from the previously plated neural progenitor cells was extracted using TRIzol
(ambion®). AD and Control cells from 48 hours and 120 hours after scratch assay and their
respective controls were used to check for APP gene expression at two different time points.
Cells were first detached from the tissue treated plates using Versene 1X (Gibco® Life
Technologies) following the previous stated protocol, which was adapted to be suitable for the
area of each well (250 uL/well to wash, and 500 uL/well to lift the cells). Once detached, cells
were centrifuged at 12,000 rpm for 5 minutes. The supernatant was removed, and the cells were
resuspended in 500uL of TRIzol, moved to 1.5 mL tubes, followed by an incubation period of
five minutes at room temperature. Then, 100 uL of Chloroform (Fisher Scientific) were added to
each tube, and cells were then vortexed for 15 seconds and incubated for three minutes at room
temperature followed by a centrifugation of 12,000 rpm for five minutes at 4°C.

After centrifugation, three phases were formed in each tube, and the top phase (aqueous one)
containing the RNA was isolated and placed in a different tube. The tubes containing the
aqueous solution were later treated with 250 uL of Isopropanol, inverted multiple times,
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incubated for 10 minutes at room temperature, and then centrifuged at 12,000 rpm for 15 minutes
at 4°C. The supernatant was then carefully isolated, and the pellet was washed with 500 uL of
ice cold 95% ethanol and centrifuged at 7,500 rpm for 5 minutes at 4°C. The ethanol was
removed, the pellet was let dry for 10 minutes and resuspended in 30 uL of molecular grade
water. The RNA was then checked for purity using the NanodropTM (Thermo Fisher Scientific)
and later stored at -20°C.

RT-PCR of Neural Progenitors Treated with Phenserine and Scratch Assay
cDNA was constructed from total RNA using the 50 Reactions SuperScript™ III First-Strand
Synthesis SuperMix for qRT-PCR kit (Thermo Fisher Scientific). Following cDNA extraction,
purity and concentration was checked using the NanodropTM (Thermo Fisher Scientific.
Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) was then performed using 4 uL
MgCl2, 10 uL 5X GoTaq Flexi Buffer, 2 uL dNTPs, 1uL GoTaqG2 Flexi DNA polymerase, 27
uL molecular grade water, 2 uL of reverse and 2 uL of forward primer and 2 uL of template.
APP, GFAP, and BIII were checked on each of the samples. The APP primer used was 147 bp
(+) GTGTTCTTTGCAGAAGATGTG, (-) CTCCACCACACCATGATG), the GFAP primer
used was 266 pb (+) 5’-GCAGAGATGATGGAGCTCAATGACC-3’ (-) and the BIII-tubulin
primer used was 239 bp (+) 5’-ATGAGGGAGATCGTGCACAT-3’(-) 5’GCCCCTGAGCGGACACTGT-3.’ The annealing temperature for BIII-tubulin and GFAP was
59°C and for APP was 48°C. The samples ran for 35 cycles.
Following PCR, gel electrophoresis was performed to check for expression of GFAP, BIIItubulin, and APP genes. A 3% agarose gel was used to perform electrophoresis at 85 volts. The
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ladder used for this procedure was the GeneRuler 1 kb Plus DNA Ladder (Thermo Scientific).
The resulting gel was then analyzed for gene expression.
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RESULTS & DISCUSSION
NSCs-iPS Cell Expansion and Differentiation
NSCs-iPS cells were cultured for six weeks on suspension flasks. Passages varied
between 1-2 passages every other week based on the confluency and/or differentiation stage of
the NSCs. Interestingly, AD NSCs-iPS cells grew bigger neurospheres, but little amount of them
were produced when compared to Control NSCs-iPS cells (Figure 5). This could be due to
differences in cell density after thawing for which NSCs-iPS cells were not counted. Stress and
improper handling of the NSCs-iPS cells resulted in some cells spontaneously differentiating,
which was highlighted by cells sticking to the bottom of the flask (Figure 5, C). When this
happened, the neurospheres in suspension were removed and placed in a different flask to
continue growing apart from spontaneously differentiated cells. At the end of expansion, there
were seven T-75 flasks containing NSCs-iPS from both AD (four flasks) and Control (three
flaks), which were used for neural differentiation.
NSCs-iPS cells previously mentioned were differentiated on the T-75 flasks for two
weeks using NT2 media. Cells were then plated at high density in seven 12-well tissue treated
plates. High density plating was used in order to obtain a monolayer and proceed with
evaluations proposed [25]. Cells were then maintained for two more weeks before treatment with
Phenserine and scratch assay. It is of note that AD cells grew slower than Control cells, which
could have resulted in variations in the density of the cells before scratch assay. If so, some wells
might have more cells than others resulting in more cells of a specific condition migrating more
than cells of other conditions.
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Neural Progenitor Cell Migration and Proliferation
Phenserine was used at 50 uM to reduce APP expression by about 50% before scratch
assay. Thus, the role of APP in the processes required for neural tissue regeneration could be
evaluated by comparing cell migration, proliferation, and differentiation on both conditions, with
and without Phenserine treatment. When comparing the Phenserine treated (P+) and non-treated
(P-) conditions, there was not statistical significance in the reduction of APP (Figure 9, C). This
may be due to APP not being significantly reduced after treatment with 50uM Phenserine on
both cell lines. Interestingly, the results suggest that APP may have been reduced more in
Control cells than in AD cells, however further studies on in vitro APP reduction by Phenserine
are required to confirm this.
Before Phenserine treatment, Vybrant™ Dio cell labeling fluorescent dye was used for
analysis of cell migration. After addition of Vybrant™ Dio and Phenserine, the scratch assay was
successfully performed and sufficient for signaling neural progenitors to repair the damaged
area. Five different replicates of the scratch assay were made, and three were selected for
quantification. Figure 6 indicates the tracking of cell migration and proliferation after 2, 24, 48,
and 120 hrs. upon scratch assay, and the respective immunofluorescence emitted by the neural
progenitor cells on different Phenserine conditions. There is statistical significance in the
immunofluorescence emitted by cells 2 hrs. after scratch and the immunofluorescence detected
from cell at 120hrs. Data on the scratch area at 120 hrs. shows similar fluorescence emission than
non-scratch area, suggesting cells may be migrating and proliferating (Figure 6 & 7).
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Cell proliferation 120 hrs. after scratch assay was examined by nuclei cell count. Nuclei
were stained with DAPI and manual count of each nucleus was performed. The average cell
count did not show any statistical significance. Nevertheless, the results on cell proliferation
showed that AD cells treated with Phenserine emit the highest immunofluorescence compared to
the other samples (Figure 6), while it represents the sample with the least amount of cell
proliferation (Figure 7). Thus, it could be possible that neuronal progenitor cells from AD
patients in which APP is reduced, may present less cell proliferation and more cell migration
rates than AD cells non treated or Control cells. These trends suggest that APP could be needed
as a regulator of proliferation, which may occur after migration in order to initiate monolayerrepair of the in vitro model of neural tissue damage.
Neural Progenitor Cell Differentiation
120 hrs. after the scratch assay, differentiation of neural progenitor cells was evaluated using anti
BIII-tubulin antibody to detect neurons and anti glial fibrillary acidic protein (GFAP) antibody to
detect glial cells after scratch was closed (Figure 8). The results do not indicate any statistical
significance between the different cell conditions for any of the progenitor cell types, but it was
shown that both, neurons and glia, are present 120 hrs. after neural tissue injury. Based on the
data collected, BIII-tubulin seems to be highly expressed on Control cells compared to AD cells,
while AD cells appear to have more positive immunostaining rates for GFAP. These findings
could indicate that APP may have a role in neural progenitor cell differentiation towards
neuronal cells in the healthy brain (Control) and towards glial cells in the diseased brain (AD). A
similar effect was shown in samples without scratch; AD NP cells seemed to have less BIIItubulin immunostaining signal than Control NP cells, which could be related to APP
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upregulation. If these assumptions were correct, then it is possible that inhibition of APP by
Phenserine enhances BIII-tubulin immunostaining. This could explain why APP levels are higher
in the diseased condition, since APP may be driving glial cell differentiation for primary neural
tissue repair (AD) and neuronal differentiation in the healthy brain (Control).
In this scratch model, the regeneration time was determined to be 120hrs. Thus, in order
to analyze when and whether GFAP, BIII- tubulin, and APP genes are regulated, RT-PCR was
performed at 48 hrs. (D2) and 120hrs (D5) after scratch (Figure 10). Both BIII-tubulin and APP
genes are expressed on all cells at all conditions at the different time points. The bands on D5 are
more intense for both genes than the bands on D2, which may indicate a higher gene expression
after neural tissue has been repaired due to full regeneration of the scratch area. Nevertheless,
RT-qPCR should be done on the samples to specifically quantify the gene expression of APP and
neuronal associated markers after a scratch assay.
APP Expression and Neuronal Cells
Neurons express high levels of APP in AD, which is one of the hallmarks in AD research.
The correlation between the amount of APP expressed in neurons is crucial to evaluate whether
or not APP affects neuronal cells. Figure 9 shows the expression of APP and BIII-tubulin
(neuronal marker) 120hrs. after scratch assay. Positive immunofluorescence for APP and BIIItubulin appear to be consistent on most cell conditions. In AD and Control conditions without
scratch, AD seems to have lower intensity of immunofluorescence response for BIII-tubulin and
APP compared to Control. AD cells non-treated with Phenserine showed signs to have lower
immunoreactivity to BIII-tubulin compared to Phenserine treated AD cells. However, there was
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not a visible difference between the immunoreactivity of APP in the Phenserine treated and nontreated cells. This data is correlated with the electrophoresis results presented on Figure 10.
Finally, for Control cells, BIII-tubulin and APP immunofluorescence signal appears higher in
non-treated cells compared to Phenserine treated cells.
These results suggest that Phenserine may decrease the amount of APP on Control cells,
but not on AD cells in vitro. Additionally, it could be inferred that the levels of APP are slightly
correlated to the number of neurons because APP may regulate neuronal differentiation and
migration after neural tissue damage. This could be due to BIII-tubulin expression and cell
migration being lower when APP is not reduced by Phenserine. Additionally, APP could be
involved in glial differentiation if it were to inhibit neuronal migration and differentiation after
neural tissue damage. Nevertheless, all these suggestions should be further evaluated when APP
can be significantly lowered by a specific Phenserine concentration in AD cells derived from iPS
cells in an in vitro model.
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Future Directions
Future studies may focus on quantifying gene expression for neuronal and glial cells
related markers as well as APP to indicate a more specific correlation between the levels of APP
and neuronal and glial cells. It is also important to optimize in this model a concentration of APP
that can reduce the amount of APP significantly enough to have more consistent and significant
results that can indicate whether or not the inhibition of APP will have a key effect on cell
migration, proliferation, and differentiation, since this study used a concentration previously used
on glioblastoma cells [22]. Furthermore, immunostaining of neural progenitor cells at earlier
time points would be beneficial to analyze how APP affects the first hours of neuroregenration in
vitro.
Further research into the specific role of APP in neurons will also lead to understanding
how its reduction will influence the functioning of the normal brain compared to the diseased
one. Thus, using specific factors for neural differentiation is recommended. Additionally, the role
of APP in glial differentiation could be further study by analyzing what specific glial progenitor
cells may be affected by APP. Finally, using specific factors and culture conditions to better
mimic the normal functioning of the brain will result in more accurate data to understand the
process behind the role of APP.
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FIGURES

Figure 1. APP Proteolytic Cleavage in Alzheimer’s Disease
The non-amyloidogenic pathway produces a soluble fragment upon cleavage by -secretase at the N-terminus and secretase at the C-terminus. Meanwhile, the amyloidogenic pathway results in the formation of a soluble fragment
and the non-soluble A protein upon the cleavage by -secretase and -secretase. The A accumulate and represent
a hallmark for AD.
Source: Robbins and Cotran Pathologic Basis of Disease. 9 th Edition
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Figure 2. Alzheimer’s Disease and Hippocampal Adult Neurogenesis
APP is thought to play important roles in the proliferation, differentiation, maturation, and survival of neural stem
cells and neural progenitor cells in the adult hippocampus. APP is also a key hallmark for Alzheimer’s disease as the
precursor protein of A oligomers. The amyloidogenic and non-amyloidogenic pathways for APP in Alzheimer’s
disease result in soluble APP (sAPP) and A & AICD respectively upon the cleavage of secretases. Roles of the key
players of Alzheimer’s disease in hippocampal neurogenesis are summarized.
Source: https://molecularneurodegeneration.biomedcentral.com/articles/10.1186/1750-1326-6-85
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Figure 3. Alzheimer’s Disease Modeled by iPS Cells
Patient specific somatic cells are reprogramed using key transcription factors and signal molecules to be
differentiated in vitro into neural progenitors. Resulting cells can be edited for mutations or transgenes, or these can
be used to represent AD specific phenotypes to study the disease. At this point cells can also be used for drug
screening or treatment with different molecules to target the disease.
Source: A.E. Mungenast et al. / Molecular and Cellular Neuroscience 73 (2016) 13–31
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A.
Source: http://austinpublishinggroup.com/biomedical-engineering/fulltext/ajbe-v1-id1016.php

Figure 4. NSCs Obtained by Dual SMAD Inhibition
Human induced pluripotent stem (hiPS) cells are differentiated first into neuroectodermal progenitors and then into
neural stem cells (NSCs) for future glial or neuronal differentiation. SMAD signaling is inhibited using Noggin,
SB431542, or dorsomorphin that act as competitor of the BMP, activin, and nodal pluripotent cell pathways
respectively. A. Pathway by which hiPS cells are differentiated into neuronal and glial cells. B. iPS cell lines 64
(AD) and C. 18 (Control) were induced to neural stem cells (NSCs) via dual SMAD inhibition using Noggin and
SB431542 for neuroectodermal lineage to be activated. PAX 6 (neuroectodermal marker) and Nanog (stemness
marker) are expressed indicating the existence of neural stem cells.
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Figure 5. Neurospheres of NSCs-iPS
Neural stem cells derived from iPS cells (NSCs-iPS) were grown and maintained for six weeks using hNSC media.
AD NSCs-iPS grew larger, but in smaller quantities, while Control NSCs-iPS neurospheres were smaller, but larger
in quantity. A. AD neurosphere passage #3. B. Control neurosphere passage #3. C. Some cells may show
spontaneous differentiation when cultured on NT2 media.
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A.

B.
Figure 6. Neural Progenitor Cell Migration & Proliferation After Scratch Assay
A. Neural progenitor cells treated with Phenserine for 16hrs followed by a scratch assay. Dio was used to track
migration and proliferation of NPCs at different time points (2hrs, 24hrs, 48hrs, and 120 hrs). B. Average
immunofluorescence emitted by neural progenitor cells upon scratch assay at different time points.
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Figure 7: Neuronal Cell Expression and Cell Count
Neural cell proliferation 120hrs after scratch assay was recorded through cell nuclei count. A. BIII-tubulin (neuronal
marker) expressed after scratch assay indicating neuronal cell proliferation from the area of scratch. B. Average
number of cell nuclei in each neuronal cell condition.

27

Figure 8. Neural Progenitor Cell Type Immunocytochemistry 120hrs after Scratch Assay
A. BIII-tubulin and GFAP were used to mark for neuronal and glial expression respectively on each control group
120 hrs. after scratch assay B. Immunofluorescence intensity for BIII-tubulin (neuronal marker) on neural progenitor
cells 120hrs after scratch assay. C. GFAP (glial marker) immunofluorescence intensity for neural progenitor cells
120hrs after scratch assay.

28

Figure 9: APP Expression in Neural Progenitor Cells 120hrs after Scratch Assay.
A. APP clone (22C11) and BIII-tubulin (neuronal marker) were used to indicate expression of APP and neurons on
neural progenitor cells of all control groups 120hrs. after scratch assay. B. Immunofluorescence intensity for BIIItubulin on neural progenitor cells 120 hrs. after scratch assay. C. APP immunofluorescence intensity 120 hrs. after
scratch assay in neural progenitor cells.
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Figure 10: RT-PCR for BIII-tubulin, GFAP, and APP expression.
Gene expression for GFAP (glia), BIII-tubulin (neurons), and APP in neural progenitor cells on day 2 (48hrs) and
day 5 (120hrs) after scratch assay. GFAP is 266 bp, BIII-tubulin is 239 bp, and APP is 147 bp long. Expression of
both BIII-tubulin and APP can be detected on different conditions on both times (D2 & D5).
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